Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

  • STATUS
    Recruiting
  • End date
    Aug 1, 2024
  • participants needed
    48
  • sponsor
    Chinese Academy of Medical Sciences
Updated on 1 September 2021

Summary

This phase I/II study was designed to evaluate the efficacy and safety of fruquintinib combination with capecitabine in maintenance treatment after first-line chemotherapy combined with cetuximab.

Description

At present, most studies use chemotherapy combined with cetuximab or cetuximab alone as the maintenance treatment scheme after the first-line regimen containing cetuximab. However, the skin reaction caused by cetuximab and frequent infusion treatment will bring inconvenience to patients. MACBETH study compared the maintenance of bevacizumab with cetuximab, although there was no significant difference in PFS between them, the Bev group seemed to convey a longer median OS. Fruquintinib is a highly selective anti angiogenesis TKI. This study aims to explore the efficacy and safety of fruquintinib combined with capecitabine in maintenance treatment after first-line chemotherapy combined with cetuximab. Both fruquintinib and capecitabine are orally given, so this regimen may provide a maintenance treatment option that is more manageable for patients in clinical practice.

Details
Condition Metastatic Colorectal Cancer
Treatment Fruquintinib Plus Capecitabine
Clinical Study IdentifierNCT05016869
SponsorChinese Academy of Medical Sciences
Last Modified on1 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with histologically confirmed metastatic colorectal adenocarcinoma
-75 years old
Eastern Cooperation Oncology Group (ECOG) performance score 0-1
At least one evaluable lesion for disease assessment according to RECIST version 1.1
Able to take oral medications
Patient have achieved CR, PR or SD after up to 8 cycles of first-line standard FOLFOX / - FOLFIRI / XELOX / xeliri + cetuximab treatment, and remained unresectable
If radiotherapy has been performed before enrollment, at least one lesion should be located outside the radiation field
Adequate organ functions as assessed by the following laboratory requirements: Leukocytes3.0x10^9/L, absolute neutrophil count1.5x10^9/L, platelet count100x10^9/L, hemoglobin9g/dL; serum bilirubin1.5x the upper limit of normal(ULN);Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)2.5x ULN; serum creatinine1.5x ULN
An expected survival of at least 12 weeks
Fertile male or female patients volunteered to use effective contraceptive methods during the study period and within 6 months after the end of treatment
Willing to provide written informed consent to study procedures

Exclusion Criteria

Patients who have received fruquintinib
Patients who have received TACE within 6 weeks before enrollment
Participated in other unapproved or unlisted drug clinical trials in China within 4 weeks before enrollment, and received corresponding experimental drug treatment
Patients with dysphagia, active peptic ulcer, intestinal obstruction, active gastrointestinal bleeding, peptic perforation, malabsorption syndrome or uncontrolled intestinal inflammatory diseases
International normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 ULN
The researchers judged clinically significant electrolyte abnormalities
At present, the patient has hypertension that cannot be controlled by drugs, which is specified as: systolic blood pressure 140 mmHg and / or diastolic blood pressure 90 mmHg
Patients currently have poorly controlled diabetes (fasting glucose level is greater than CTCAE grade 2 after regular treatment)
Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.)
Active or uncontrolled severe infection grade 2 according to National Cancer Institute Common Toxicity (NCI-CTC) criteria
Uncontrolled central nervous system metastasis or previous brain metastasis
Other malignant tumors in the past 5 years, except for skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ
Any kind of concurrent cardiac disease with clinical meanings, such as cardiovascular accident, myocardial infarction, thromboembolism or hemorrhage within 6 months before enrollment, congestive heart failure New York Heart Association (NYHA) class 2; ventricular arrhythmias requiring drug treatment; LVEF < 50%
With positive urine protein and 24-hour urinary protein content>1g
Have a tendency of bleeding or clotting
Known human immunodeficiency virus (HIV) infection; known history of clinically significant liver disease, including viral hepatitis
The target lesions have received brachytherapy (radioactive particle implantation) within 60 days before admission
Unrelieved toxic reactions higher than CTCAE V5.0 grade 1 caused by any previous anti-cancer treatment, excluding hair loss, lymphopenia and neurotoxicity grade 2 caused by oxaliplatin
With any illness or medical conditions that may jeopardize the patient's compliance or interfere the analyses or judgements of study results
Pregnancy or lactation at the time of study entry
With fertility but refuse to contraception
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note